Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 4, pp. 322-334
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 878-886
Open Access | Times Cited: 55
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1379-1389
Closed Access | Times Cited: 32
Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics
Yueyue Gao, Tong Wu, Xianan Tang, et al.
GeroScience (2023) Vol. 45, Iss. 3, pp. 1775-1790
Open Access | Times Cited: 29
Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
Simon Mucha, Prabalini Rajendram
Current Oncology (2023) Vol. 30, Iss. 5, pp. 5003-5023
Open Access | Times Cited: 12
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
Michael P. Randall, Michael A. Spinner
Cancers (2023) Vol. 15, Iss. 18, pp. 4509-4509
Open Access | Times Cited: 11
Topological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma
Hiromichi Takahashi, Shun Ito, Yoko Nakanishi, et al.
Annals of Hematology (2025)
Open Access
Computational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
Antonio Santisteban‐Espejo, C. de la Fuente, Alipio Mangas, et al.
Journal of Clinical Pathology (2025), pp. jcp-209848
Closed Access
A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder
Himesh B. Zaver, Gautham Prakash, Samuel Plant, et al.
ACG Case Reports Journal (2025) Vol. 12, Iss. 2, pp. e01618-e01618
Open Access
Efficacy of Brentuximab-Vedotin Combined with PD-1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma with ASCT Consolidation and Maintenance Therapy: A Phase 2 Clinical Trial
Isaac Barrera-Chávez, Juan Carlos Viloria Álvarez, Verónica Zendejas Sánchez, et al.
Indian Journal of Hematology and Blood Transfusion (2025)
Closed Access
Managing HIV-Associated Hodgkin Lymphoma During the COVID-19 Pandemic: Case Report and Literature Review
Monica-Daniela Padurariu-Covit, Mihaela Andreescu, Elena Niculeț, et al.
Viruses (2025) Vol. 17, Iss. 3, pp. 404-404
Open Access
Leveraging social media data to study disease and treatment characteristics of Hodgkin’s lymphoma Using Natural Language Processing methods
Zasim Azhar Siddiqui, M. M. Pathan, Sabina O. Nduaguba, et al.
PLOS Digital Health (2025) Vol. 4, Iss. 3, pp. e0000765-e0000765
Open Access
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics
Nick Veltmaat, Geok Wee Tan, Yujie Zhong, et al.
Annals of Hematology (2025)
Open Access
Advances in the Pathophysiology, Diagnosis, and Treatment of Lymphomas: A Comprehensive Overview
Maaweya Jabareen, Muhammad Al-Sweity, Wasef Alhroub, et al.
IntechOpen eBooks (2025)
Closed Access
Patients’ experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study
Yiwen Mao, Lihong Huang, Haitao Ruan, et al.
Supportive Care in Cancer (2023) Vol. 31, Iss. 5
Open Access | Times Cited: 10
Is Short-Course Antibiotic Therapy Suitable for Pseudomonas aeruginosa Bloodstream Infections in Onco-hematology Patients With Febrile Neutropenia? Results of a Multi-institutional Analysis
Xiaomeng Feng, Chenjing Qian, Yuping Fan, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 3, pp. 518-525
Open Access | Times Cited: 10
Multimodality imaging of extra-nodal lymphoma in the head and neck
Hoi Ming Kwok, F H Ng, Chi Man Chau, et al.
Clinical Radiology (2022) Vol. 77, Iss. 8, pp. e549-e559
Closed Access | Times Cited: 16
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
Roberto Tamma, Giuseppe Ingravallo, Francesco Gaudio, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2803-2803
Open Access | Times Cited: 8
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies
Simonetta Viviani, Anna Vanazzi, Samuele Frassoni, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 4, pp. 460-471
Closed Access | Times Cited: 2
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis
Dahlia Sano, Nicholas Liu, Scott M. Knowles, et al.
Current Oncology (2024) Vol. 31, Iss. 5, pp. 2598-2609
Open Access | Times Cited: 2
Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study
Marco Picardi, Claudia Giordano, Novella Pugliese, et al.
British Journal of Haematology (2022) Vol. 198, Iss. 5, pp. 847-860
Open Access | Times Cited: 10
The role of viruses in HIV-associated lymphomas
Kathryn Lurain, Ramya Ramaswami, Robert Yarchoan
Seminars in Hematology (2022) Vol. 59, Iss. 4, pp. 183-191
Open Access | Times Cited: 9
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
Allison Winter, Nicholas Liu, Andy Surinach, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 7, pp. 527-534
Open Access | Times Cited: 5
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
Susan K. Parsons, Kristina S. Yu, Nicholas Liu, et al.
JCO Oncology Practice (2023) Vol. 19, Iss. 6, pp. e867-e876
Open Access | Times Cited: 4
Fast Track Management of Primary Thyroid Lymphoma in the Very Elderly Patient
Pierre Yves Marcy, Frédéric Bauduer, Juliette Thariat, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5816-5827
Open Access | Times Cited: 4
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Huan Xie, Jing Zhang, Ran B. Luo, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top